Loading...
Market
Average price reduction of liraglutide by end of 2024
4
Resolution / Starting Odds
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Average price data from pharmaceutical market reports
Story
Teva Launches First Generic GLP-1 Drug, Liraglutide (Victoza)
Jun 26, 2024, 10:01 AM
On June 24, 2024, Teva launched the first generic version of Novo Nordisk's GLP-1 receptor agonist drug, liraglutide, known commercially as Victoza. This generic introduction marks a significant milestone in the diabetes and obesity medication market. The higher dose of 3mg daily, which is used for obesity, could potentially make the treatment more accessible to those in need. However, experts are cautious about immediate price reductions, citing market inertia and other factors.
View original story
Similar markets
No reduction • 33%
Up to 25% reduction • 33%
More than 25% reduction • 33%
No reduction • 33%
Up to 25% reduction • 33%
More than 25% reduction • 33%
None • 25%
1 company • 25%
2 companies • 25%
3 or more companies • 25%
Significant improvement in affordability perception • 25%
Slight improvement in affordability perception • 25%
No change in affordability perception • 25%
Worsening perception of affordability • 25%
Less than 20% • 33%
20% - 50% • 33%
More than 50% • 34%